Futura Medical’s Partnership with Cooper Consumer Health Extended to 2029

Futura Medical, a pharmaceutical company focused on developing innovative products for sexual health and pain relief has prolonged its sole licensing arrangement with Cooper Consumer Health until 2029. 

Futura Medical will maintain the rights to advertise Eroxon, a gel treatment for erectile dysfunction throughout Europe. 

This treatment marks the first of its kind of a pan-European topical remedy for ED that is accessible without a prescription. 

Following its initial introduction in the UK and Belgium last year, further expansion into Italy, Spain, and France, is scheduled for this year. 

The head executive at Futura Medical, James Barder, commented, “The award-winning launch of Eroxon was a key milestone in our partnership with Cooper and the success of our collaboration makes this extension an easy decision for both parties.” 

Chief officer of Cooper Consumer Health, Bart Meermans, stated, “Eroxon is an exciting new innovation for the erectile dysfunction market, and we look forward to working closely with Futura with the continuing launches of Eroxon across our markets.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.